Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

D. M. GRAHAM LABS RECEIVED 10 ANDA APPROVALS IN 1985

Executive Summary

D. M. GRAHAM LABS RECEIVED 10 ANDA APPROVALS IN 1985, the generic mfr. told "The Pink Sheet" in a recent letter. Eight of the approvals were for acetaminophen/butalbital combos, while two covered acetaminophen/hydrocodone products. In addition, the company said that there were eight ANDAs issued in 1985 "for our products in the names of our customers and for which we provided the bulk of the submission." This group includes three approvals for Fisons, two each for Gilbert Labs and Carnrick Labs and one for Mayrand. "Five ANDAs have been issued for our products in the names of our customers but these, by agreement, cannot be disclosed," the letter stated. Calling 1985 "a record year for approvals for D. M. Graham Labs," President Dean Graham, PhD, said that the results are indicative of "how effectively the FDA is currently processing their backlog." The exec noted that in addition to the ANDA approvals, the company received four NDAs during the year. Graham Labs has also apparently improved its standing with FDA inspectors in recent years. An establishment inspection report dated 1982 noted that the firm had "a history of manufacturing and shipping new drugs without approved NDAs or ANDAs and . . . of general manufacturing procedures problems." Reportedly, the company has not received an FDA reg letter since July 1982, however.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS010035

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel